American Biogenetic Sciences gains patent for antibody labelling method:
This article was originally published in Clinica
Executive Summary
American Biogenetic Sciences has received a US patent covering methods for radiolabelling biomolecules bearing sulfhydryl groups that do not require the use of acidic or basic solutions. The method was developed for labelling the Fab' fragment of the company's MH-1 antibody, an imaging agent for the detection of thrombi such as deep vein thrombosis and pulmonary embolism. It is also applicable to other monoclonal antibodies in the company's R&D portfolio and "has licence potential to interested third parties for their individual needs," according to the Copiague, New York-based company.